Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : progenics -- Ignore unavailable to you. Want to Upgrade?

To: Angelo who wrote (33)	7/27/1999 11:23:00 AM
From: John Dwyer	Read Replies (1) \| Respond to of 139

We should see some interim results soon, hopefully by year end. They should file for FDA review early next year if all goes well. I think there is a high probability for approval since they are comparing GMK to interferon. Since IFN has such horrible side effects, I would suspect that GMK doesn't need to have much better efficacy to be approved. Phase II results showed a reasonable efficacy, hopefully they can demonstrate similar results here in Phase III. Call or email Progenics for their investors pack if you haven't done so. It's quite good. Good luck! John